A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine ...

Dr. Westerweel concludes, "Digital PCR for BCR::ABL is a valuable and reliable tool to aid clinical decision making in CML." More information: Camille Kockerols et al, BCR::ABL1 Deep Molecular ...

Ascentage Pharma Group International’s AAPG share price has dipped by 6.94%, which has investors questioning if this is right ...

The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 ...

One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.

Commenting on the findings of the study, Dr. Westerweel says, "BCR::ABL1 digital PCR was found to accurately quantify BCR::ABL1 around the level of 0.0023% on the International Scale, which is the ...

However, despite its well-understood role in CML, little is known about the evolution of this fusion gene, the rate at which cells with BCR::ABL1 start to multiply, and how this contributes to ...